Curated News
By: NewsRamp Editorial Staff
March 11, 2025
GeoVax Labs CEO to Present at 37th Annual Roth Conference on Immunotherapies and Vaccines
Discuss on Reddit
LinkedIn
Telegram
GithubTLDR
- GeoVax Labs, Inc. announces CEO presentation at Roth Conference, offering investors insight and potential advantage.
- GeoVax Labs, Inc. Chairman & CEO, David Dodd, to present at 37th Annual Roth Conference in Dana Point, CA on March 17, 2025.
- GeoVax Labs, Inc. develops immunotherapies and vaccines against cancers and infectious diseases, making strides towards a healthier future.
- GeoVax Labs, Inc. CEO, David Dodd, to engage in a fireside chat at Roth Conference, presenting cutting-edge biotechnology advancements.
Impact - Why it Matters
This news highlights GeoVax's advancements in developing vaccines against infectious diseases and cancers, including a next-generation COVID-19 vaccine. Investors and stakeholders in the biotechnology and healthcare industries should pay attention to GeoVax's presentation at the conference.
Summary
GeoVax Labs, Inc. announced that its Chairman and CEO, David Dodd, will present at the 37th Annual Roth Conference in California. The presentation will focus on the company's development of immunotherapies and vaccines against cancers and infectious diseases.
GeoVax is a biotechnology company with a lead clinical program for a next-generation COVID-19 vaccine. The company also has a strong IP portfolio and experienced leadership team driving value creation.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, GeoVax Labs CEO to Present at 37th Annual Roth Conference on Immunotherapies and Vaccines
